Page last updated: 2024-10-15

oxypurinol

Description

Oxypurinol: A xanthine oxidase inhibitor. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

alloxanthine : A pyrazolopyrimidine that is 4,5,6,7-tetrahydro-H-pyrazolo[3,4-d]pyrimidine substituted by oxo groups at positions 4 and 6. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID135398752
CHEMBL ID859
CHEBI ID28315
SCHEMBL ID1438699
SCHEMBL ID39154
SCHEMBL ID8256426
MeSH IDM0015696

Synonyms (102)

Synonym
AKOS002337397
6-hydroxy allopurinol
1h-pyrazolo[3,4-d]pyrimidine-4,6-diol
oxoallopurinol
nsc-76239
1h-pyrazolo[3,6(5h,7h)-dione
1h-pyrazolo[3,6-diol
nsc76239
bw 555
1h-pyrazolo[3, 4,6(5h,7h)-dione
b. w. 55-5
oxipurinol
C07599
oxypurinol
alloxanthine
2465-59-0
oxypurinol, >=98% (hplc)
1h-pyrazolo[3,4-d]pyrimidine-4,6(5h,7h)-dione
CHEBI:28315 ,
D02365
oxypurinol (usan)
oxipurinol (inn)
epa pesticide chemical code 447509
alloxanthin (van)
ai3-50432
nsc 76239
bw 55-5
ossipurinolo [dcit]
1h-pyrazolo(3,4-d)pyrimidine-4,6-diol
1h-pyrazolo(3,4-d)pyrimidine,4,6(5h,7h)-dione
einecs 219-570-9
4,6-dihydroxypyrazolo(3,4-d)pyrimidine
1h-pyrazolo(3,4-d)pyrimidine-4,6(5h,7h)-dione
1h-pyrazolo(3,4-d)pyrimidine, 4,6(5h,7h)-dione
oxipurinolum [inn-latin]
smr000471889
MLS001332657
MLS001332658
CHEMBL859
AKOS005166855
FT-0667156
NCGC00247052-01
unii-g97oze5068
oxipurinol [inn]
ossipurinolo
g97oze5068 ,
oxipurinolum
oxypurinol [usan]
dtxsid4035209 ,
NCGC00255415-01
dtxcid2015209
tox21_301220
cas-2465-59-0
SCHEMBL1438699
9h-purine-2,8-dione
A817425
HMS2234G23
BP-30013
184764-63-4
2h-pyrazolo[3,4-d]pyrimidine-4,6(5h,7h)-dione
1h-pyrazolo[3,4-d]pyrimidine-4,6(2h,5h)-dione
187486-05-1
FT-0648966
4,6-dihydroxypyrazolo[3,4-d]pyrimidine
AB02032
oxipurinol [who-dd]
HMS3373G16
bdbm50423777
DB05262
AKOS022171676
SCHEMBL39154
1,2-dihydropyrazolo[4,3-e]pyrimidine-4,6-dione
4,5,6,7-tetrahydro-4,6-dioxo-pyrazolo-[3,4-d]-pyrimidine
SCHEMBL8256426
W-202026
6-hydroxy-1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-one #
1h-pyrazolo[3,4-d]pyrimidin-4,6-diol
1h,3h,9h-alloxanthine
6-hydroxypyrazolo[3,4-d]pyrimidin-4-one
187486-06-2
mfcd00056934
1h,4h,5h,6h,7h-pyrazolo[3,4-d]pyrimidine-4,6-dione
oxypurinol, analytical standard
2h,4h,5h,6h,7h-pyrazolo[3,4-d]pyrimidine-4,6-dione
CS-0016170
2h-pyrazolo-[3,4-d]pyrimidine-4,6-(5h,7h)-dione
FT-0740012
4h-pyrazolo[3,4-d]pyrimidin-4-one,1,2-dihydro-6-hydroxy-
Q410588
DS-14873
CCG-321461
AMY15720
HY-19657
1,2-dihydro-4h-pyrazolo[3,4-d]pyrimidine-4,6(5h)-dione
oxypurinol 100 microg/ml in water
1,7-dihydro-4h-pyrazolo[3,4-d]pyrimidine-4,6(5h)-dione
4h-pyrazolo[3,4-d]pyrimidin-4-one, 1,2-dihydro-6-hydroxy-
1,7-dihydropyrazolo[3,4-d]pyrimidine-4,6-dione
EN300-1268328
4,6-dihydroxy-1h-pyrazolo[3,4-d]pyrimidine
SY009072
Z3015154132

Research Excerpts

Overview

Oxypurinol is a better hydroxyl radical scavenger than is allopurinOL (k2 approx. )

ExcerptReference
"Oxypurinol is a better hydroxyl radical scavenger than is allopurinol (k2 approx."( Allopurinol and oxypurinol are hydroxyl radical scavengers.
Grootveld, M; Gutteridge, JM; Halliwell, B; Moorhouse, PC; Quinlan, JG, 1987
)

Actions

ExcerptReference
"Oxypurinol did not produce clinical improvements in unselected patients with moderate-to-severe heart failure. "( Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study.
Brown, J; Colucci, WS; Fisher, C; Freudenberger, R; Givertz, MM; Hare, JM; Liu, P; Mangal, B; Mann, DL; Schwarz, RP, 2008
)

Treatment

Pulse wave velocities remained unchanged from baseline throughout the experiment. Treatment with oxypurinol (20 mg kg-1) before ischaemia and before recirculation almost completely abolished the rise in radical production.

ExcerptReference
"In oxypurinol-treated rats, pulse wave velocities remained unchanged from baseline throughout the experiment, signifying preserved vascular health."( Dietary inhibition of xanthine oxidase attenuates radiation-induced endothelial dysfunction in rat aorta.
Attarzadeh, DO; Berkowitz, DE; Bhunia, AK; Kim, JH; Lim, HK; Nyhan, D; Ryoo, S; Santhanam, L; Sevinc, B; Shoukas, AA; Soucy, KG; Vazquez, ME, 2010
)
"Oxypurinol treatments did not reduce weight loss in the right hemisphere."( Oxypurinol administration fails to prevent hypoxic-ischemic brain injury in neonatal rats.
Feng, Y; Huang, M; LeBlanc, MH; Shi, W, 2003
)
"Pretreatment with oxypurinol, an inhibitor of xanthine oxidase, had a slight but insignificant effect on the CL response produced by aortic rings from control animals but significantly reduced CL response to aortic rings from cholesterol-fed rabbits."( Vascular release of superoxide radicals is enhanced in hypercholesterolemic rabbits.
Bode-Böger, S; Böger, RH; Brandes, RP; Dwenger, A; Frölich, JC; Kienke, S; Lichtlen, PR; Mügge, A, 1994
)
"Treatment with oxypurinol reduced the aspartate aminotransferase, alanine aminotransferase, and bilirubin values by 26-47% but did not alter the increased lipid peroxidation of mitochondria and microsomes."( Effect of oxypurinol, a xanthine oxidase inhibitor, on hepatic injury in the bile duct-ligated rat.
Devereaux, MW; Khandwala, R; Sokol, RJ, 1998
)
"BCEC treated with oxypurinol, indomethacin, or N(G)-nitro-L-arginine methyl ester showed suppression of LDH release."( Reactive oxygen species in reoxygenation injury of rat brain capillary endothelial cells.
Nagashima, T; Tamaki, N; Wu, S; Yamaguchi, M, 1998
)
"Pretreatment with oxypurinol (20 mg kg-1) before ischaemia and before recirculation almost completely abolished the rise in radical production at recirculation."( ESR-measurement of production of oxygen radicals in vivo before and after renal ischaemia in the rabbit.
Akerlund, S; Bratell, S; Haraldsson, G; Jonsson, O; Nilsson, U; Pettersson, S; Scherstén, T, 1992
)
"Treatment with oxypurinol radical scavenger and xanthine oxidoreductase inhibitor diminished the morphological changes, the loss of energy-rich nucleotides and the TBA-RS accumulation."( Protective influence of oxypurinol on the trinitrobenzene sulfonic acid(TNB) model of inflammatory bowel disease in rats.
Buntrock, P; Gerber, G; Grune, T; Schneider, W; Siems, WG; Werner, A, 1992
)
"Pretreatment with oxypurinol (1000 mg/kg, s.c.) also ameliorated the paraquat toxicity in rats."( The role of xanthine oxidase in paraquat intoxication.
Kitazawa, Y; Matsubara, M; Takeyama, N; Tanaka, T, 1991
)

Pharmacokinetics

The study was to standardize and validate a sensitive high-performance liquid chromatography-mass spectrometric (HPLC-MS/MS) method. The developed assay was successfully applied in an oral pharmacokinetic study of allopurinol, oxypurinols.

ExcerptReference
"6 hours after administration, has an elimination half-life of 3 hours, and steady-state concentrations in the therapeutic range."( Pharmacokinetics and metabolism of allopurinol riboside.
Danso, K; Desjardins, RE; Nelson, DJ; Pamplin, CL; Shapiro, TA; Were, JB, 1991
)
" Furthermore, the plasma oxipurinol half-life was increased from 27."( Sustained reductions in oxipurinol renal clearance during a restricted diet.
Berlinger, WG; Kitt, TM; Park, GD; Spector, R; Tsalikian, E, 1987
)
" Allopurinol controlled release tablets (Sigapurol CR), containing 200 mg of the drug characterized by rapid absorption and 100 mg characterized by pH-dependent delivery, were identified as a formulation with advantages pharmacokinetic properties."( [Clinical pharmacokinetics of allopurinol. 3. Allopurinol/oxipurinol pharmacokinetics following administration of a controlled release allopurinol preparation].
Fenner, H; Gikalov, I; Radivojevich, F; Schiemann, O, 1986
)
"02), and the plasma oxypurinol half-life increased nearly threefold from 17."( The effect of dietary protein on the clearance of allopurinol and oxypurinol.
Berlinger, WG; Park, GD; Spector, R, 1985
)
"In a pharmacokinetic study with 6 healthy volunteers the parameters for allopurinol and oxipurinol were compared following a single dose of allopurinol and multiple application of the drug."( [The clinical pharmacokinetics of allopurinol. 2. Allopurinol/oxypurinol pharmacokinetics following allopurinol in single doses and multiple application].
Fenner, H; Gikalov, I; Schiemann, O, 1985
)
"In a randomized cross-over study with 10 volunteers two different commercial preparations of allopurinol (Remid and standard) were tested by reversed-phase HPLC with respect to their pharmacokinetic behaviour."( [Pharmacokinetic studies on plasma elimination half-life of oxipurinol (author's transl)].
Bader, B; Harries, EH; Lach, HJ; Schnitker, J, 1982
)
" The possibility of a pharmacokinetic interaction between the anti-viral agent, famciclovir and allopurinol has been investigated in twelve healthy male volunteers following a single oral dose of famciclovir (500 mg) in the presence and absence of steady-state levels of allopurinol (300 mg)."( Lack of a pharmacokinetic interaction between oral famciclovir and allopurinol in healthy volunteers.
Fowles, SE; Laroche, J; Pratt, SK; Prince, WT, 1994
)
"The purpose of this investigation was to determine the pharmacokinetic disposition of intravenous allopurinol and its metabolite oxypurinol in neonates with the hypoplastic left heart syndrome (HLHS) and to evaluate the subsequent degree of xanthine oxidase inhibition using serum uric acid as a marker."( The pharmacokinetics of injectable allopurinol in newborns with the hypoplastic left heart syndrome.
Clancy, RR; Davis, LE; Jacobs, ML; Krawczeniuk, MM; McGaurn, SP; Murphy, JD; Norwood, WI, 1994
)
" Pharmacokinetic parameters were determined for elimination half-life, clearance, volume of distribution, and mean residence time."( The pharmacokinetics of injectable allopurinol in newborns with the hypoplastic left heart syndrome.
Clancy, RR; Davis, LE; Jacobs, ML; Krawczeniuk, MM; McGaurn, SP; Murphy, JD; Norwood, WI, 1994
)
"In the present study we have investigated the use of caffeine, administered in the form of instant coffee, as a prodrug for 1MX to validate the use of the 1MU:1MX ratio following caffeine administration as a pharmacodynamic measure of oxypurinol effect on xanthine oxidase."( 1-Methylxanthine derived from caffeine as a pharmacodynamic probe of oxypurinol effect.
Birkett, DJ; Day, RO; Lillywhite, KJ; Miners, JO; Valente, L, 1997
)
"To determine bioavailability and pharmacokinetic parameters for allopurinol and its active metabolite, oxypurinol."( Bioavailability and pharmacokinetics of intravenously and orally administered allopurinol in healthy beagles.
Bartges, JW; Bird, KA; Chen, M; Felice, LJ; Koehler, LA; Osborne, CA; Sawchuk, RJ; Ulrich, LK, 1997
)
" The bioavailability of allopurinol, and pharmacokinetic parameters of allopurinol and oxypurinol after oral administration of allopurinol, are not affected by administration with food."( Bioavailability and pharmacokinetics of intravenously and orally administered allopurinol in healthy beagles.
Bartges, JW; Bird, KA; Chen, M; Felice, LJ; Koehler, LA; Osborne, CA; Sawchuk, RJ; Ulrich, LK, 1997
)
" From these data, pharmacokinetic parameters were calculated."( Influence of two diets on pharmacokinetic parameters of allopurinol and oxypurinol in healthy beagles.
Bartges, JW; Bird, KA; Chen, M; Felice, LJ; Koehler, LA; Osborne, CA; Ulrich, LK, 1997
)
"There is no influence of diet on pharmacokinetic parameters of allopurinol or oxypurinol."( Influence of two diets on pharmacokinetic parameters of allopurinol and oxypurinol in healthy beagles.
Bartges, JW; Bird, KA; Chen, M; Felice, LJ; Koehler, LA; Osborne, CA; Ulrich, LK, 1997
)
"25) as was the area under the oxipurinol plasma concentration-time curve, AUC (260+/-46 and 166+/-23 microgram ml-1 h, respectively), the pharmacodynamic effect of oxipurinol was smaller in elderly than young subjects (time-dependent decrease of plasma uric acid 83+/-30 microgram ml-1 h in elderly compared with 176+/-21 in young controls)."( Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects.
Krivanek, P; Oberbauer, R; Turnheim, K, 1999
)
" Pharmacokinetic and pharmacodynamic parameters were analysed using two-way ANOVA."( Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects.
Day, RO; Graham, GG; McLachlan, AJ; Stocker, SL; Williams, KM, 2008
)
"To investigate the pharmacokinetic and pharmacodynamic interaction between probenecid and oxypurinol (the active metabolite of allopurinol) in patients with gout."( Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout.
Day, RO; Graham, GG; McLachlan, AJ; Stocker, SL; Williams, KM, 2011
)
"A one compartment pharmacokinetic model with first order absorption best described the oxypurinol concentration-time data."( The pharmacokinetics of oxypurinol in people with gout.
Day, RO; Graham, GG; Kirkpatrick, CM; McLachlan, AJ; Savic, RM; Stocker, SL; Williams, KM, 2012
)
"In conclusion, this first established pharmacokinetic model provides a tool to achieve target oxypurinol plasma concentrations, thereby optimizing the effectiveness and safety of allopurinol therapy in gouty patients with various degrees of renal impairment."( The pharmacokinetics of oxypurinol in people with gout.
Day, RO; Graham, GG; Kirkpatrick, CM; McLachlan, AJ; Savic, RM; Stocker, SL; Williams, KM, 2012
)
"The aims of this study were to develop a population pharmacokinetic model for allopurinol and oxypurinol and to explore the influence of patient characteristics on allopurinol and oxypurinol pharmacokinetics."( The population pharmacokinetics of allopurinol and oxypurinol in patients with gout.
Barclay, ML; Duffull, SB; Holford, NH; Merriman, TR; Stamp, LK; Wright, DF, 2013
)
"The pharmacokinetic model provides a means of predicting the allopurinol dose required to achieve target oxypurinol plasma concentrations for patients with different magnitudes of renal function, different body mass and with or without concomitant diuretic use."( The population pharmacokinetics of allopurinol and oxypurinol in patients with gout.
Barclay, ML; Duffull, SB; Holford, NH; Merriman, TR; Stamp, LK; Wright, DF, 2013
)
" The developed assay was successfully applied in an oral pharmacokinetic study of allopurinol, oxypurinol and lesinurad in rats."( Ultra-performance hydrophilic interaction liquid chromatography coupled with tandem mass spectrometry for simultaneous determination of allopurinol, oxypurinol and lesinurad in rat plasma: Application to pharmacokinetic study in rats.
Alam, O; Ezzeldin, E; Herqash, RN; Iqbal, M, 2019
)
" The validated lesinurad plasma quantification method was successfully applied for the pharmacokinetic evaluations to support the clinical studies in renal impaired patients."( The Effects of Special Patient Population Plasma on Pharmacokinetic Quantifications Using LC-MS/MS.
Nguyen, M; Sun, L; Wilson, DM; Yeh, LT; Zhou, D, 2019
)
" With the confirmation that there is no impact on quantification from the matrix, the bioanalytical method can be used to support the pharmacokinetic evaluations for clinical studies in special populations."( The Effects of Special Patient Population Plasma on Pharmacokinetic Quantifications Using LC-MS/MS.
Nguyen, M; Sun, L; Wilson, DM; Yeh, LT; Zhou, D, 2019
)
" The purpose of the present study was to standardize and validate a sensitive high-performance liquid chromatography-mass spectrometric (HPLC-MS/MS) method to determine the concentration of allopurinol and its active metabolite oxypurinol in canine urine for clinical pharmacokinetic investigation."( Detection of allopurinol and oxypurinol in canine urine by HPLC/MS-MS: Focus on veterinary clinical pharmacokinetics.
Azeredo, FJ; Barrouin-Melo, SM; de Jesus, C; Godoy, ALPC; Gonçalves, RS; Lanchote, VL; Larangeira, DF; Marques, MP; Rocha, A, 2020
)
"Q141K had a longer half-life (34."( Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics.
Brackman, DJ; Garcia-Cremades, M; Giacomini, KM; Savic, RM; Sirota, M; Vora, B; Zou, L, 2021
)
"The aim of this study was to quantify identifiable sources of variability, including key pharmacogenetic variants in oxypurinol pharmacokinetics and their pharmacodynamic effect on serum urate (SU)."( Population pharmacokinetics, pharmacodynamics and pharmacogenetics modelling of oxypurinol in Hmong adults with gout and/or hyperuricemia.
Brundage, RC; Culhane-Pera, KA; Roman, YM; Straka, RJ; Wen, YF, 2023
)
" A sequential population pharmacokinetic pharmacodynamics (PKPD) analysis with non-linear mixed effects modelling was performed."( Population pharmacokinetics, pharmacodynamics and pharmacogenetics modelling of oxypurinol in Hmong adults with gout and/or hyperuricemia.
Brundage, RC; Culhane-Pera, KA; Roman, YM; Straka, RJ; Wen, YF, 2023
)

Bioavailability

Allopurinol's bioavailability and pharmacokinetic parameters are not affected by administration with food.

ExcerptReference
"Studies of the Clinical Pharmacokinetics of Allopurinol/3rd Communication: Allopurinol/oxipurinol bioavailability and pharmacokinetics following the administration of a controlled release allopurinol formulation."( [Clinical pharmacokinetics of allopurinol. 3. Allopurinol/oxipurinol pharmacokinetics following administration of a controlled release allopurinol preparation].
Fenner, H; Gikalov, I; Radivojevich, F; Schiemann, O, 1986
)
" A capacity limited absorption process for allopurinol, suggested from the results of a study on the allopurinol bioavailability from different formulations, could not be proved in the range of single doses between 200 and 600 mg resp."( [The clinical pharmacokinetics of allopurinol. 1. Allopurinol absorption sites and dose proportionality of allopurinol/oxipurinol bioavailability].
Fenner, H; Gikalov, I; Haertel, M; Hugemann, B; Schiemann, O; Schuster, O, 1985
)
" The absolute systemic bioavailability of the oral tablet was 67% +/- 23%, while the allopurinol rectal suppositories produced no measurable plasma concentrations of allopurinol or oxipurinol in any of the subjects."( Allopurinol kinetics and bioavailability. Intravenous, oral and rectal administration.
Appelbaum, SJ; Dorr, RT; Mayersohn, M; Perrier, D, 1982
)
" The bioavailability of oral allopurinol computed from plasma data was 90."( Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide.
Breithaupt, B; Tittel, M, 1982
)
"The relative bioavailability of two commercial preparations of 100 mg and 300 mg allopurinol tablets was examined in two groups of 16 healthy human subjects, one for each dosage level."( The bioavailability of two commercial preparations of allopurinol tablets.
Kleinberg, SI; Marcus, M; Tse, FL, 1982
)
" The CI of Cmax of allopurinol slightly exceeded the upper limit of 130%, so that bioequivalence was not confirmed with regard to the rate of bioavailability of the parent compound."( Bioequivalence of allopurinol preparations: to be assessed by the parent drug or the active metabolite?
de Vries, JX; Ittensohn, A; Kreiner, C; Stenzhorn, G; Voss, A; Walter-Sack, I; Weber, E, 1993
)
" The bioavailability of allopurinol was low (14."( The pharmacokinetics or oral and intravenous allopurinol and intravenous oxypurinol in the horse.
Dunnett, M; Mills, PC; Smith, NC, 1995
)
"Oxipurinol is well absorbed and sufficiently effective in hyperuricemic patients when administered as a rapid release preparation of oxipurinol sodium."( Uric acid lowering effect of oxipurinol sodium in hyperuricemic patients - therapeutic equivalence to allopurinol.
de Vries, JX; Ernst, B; Frei, M; Kolb, S; Kosmowski, J; Priebe, U; Schroder, HE; Slotty, C; Voss, A; Walter-Sack, I; Weber, A; Wegscheider, K, 1996
)
"To determine bioavailability and pharmacokinetic parameters for allopurinol and its active metabolite, oxypurinol."( Bioavailability and pharmacokinetics of intravenously and orally administered allopurinol in healthy beagles.
Bartges, JW; Bird, KA; Chen, M; Felice, LJ; Koehler, LA; Osborne, CA; Sawchuk, RJ; Ulrich, LK, 1997
)
" The bioavailability of allopurinol, and pharmacokinetic parameters of allopurinol and oxypurinol after oral administration of allopurinol, are not affected by administration with food."( Bioavailability and pharmacokinetics of intravenously and orally administered allopurinol in healthy beagles.
Bartges, JW; Bird, KA; Chen, M; Felice, LJ; Koehler, LA; Osborne, CA; Sawchuk, RJ; Ulrich, LK, 1997
)
" The relative bioavailability with respect to a reference preparation for AUC related to oxipurinol was 98."( [The bioequivalence of a new allopurinol tablet formulation in comparison to a reference formulation].
Buchberger, D; Läuter, J; Metzner, JE; Pech, R, 1997
)
"The relative bioavailability of allopurinol from two tablet preparations (Uribenz vs."( Bioequivalence of allopurinol-containing tablet preparations.
Barthel, W; Haustein, KO; Hüller, G, 1999
)
" These observations reveal that XO-derived reactive oxygen species significantly contribute to impaired coronary NO bioavailability in CAD and that XO inhibition represents an additional treatment concept for inflammatory vascular diseases that deserves further investigation."( Oxypurinol improves coronary and peripheral endothelial function in patients with coronary artery disease.
Baldus, S; Berger, J; Chumley, P; Freeman, BA; Heitzer, T; Koss, K; Köster, R; Meinertz, T; Münzel, T; Ostad, MA; Rudolph, V; Staude, HJ; Thuneke, F; Warnholtz, A, 2005
)
" The flow reversal causes the production of superoxides (O(2)(-)), which scavenge nitric oxide (NO), leading to a decrease in NO bioavailability and endothelial dysfunction."( NADPH oxidase has a directional response to shear stress.
Godbole, AS; Guo, X; Kassab, GS; Lu, X, 2009
)
"5 μmol/l, 24 h) of DES resulted in a marked reduction in endothelial NO• bioavailability determined by ESR (electron spin resonance), while 17β-oestradiol instead increased NO• production as expected."( Inhibition of XO or NOX attenuates diethylstilbestrol-induced endothelial nitric oxide deficiency without affecting its effects on LNCaP cell invasion and apoptosis.
Cai, H; Nguyen, A; Youn, JY, 2012
)

Dosage Studied

We aimed to determine the appropriateness of allopurinol dosing according to current guidelines and to assess the relationship between plasma creatinine, oxypur inol and urate. Indomethacin given at therapeutic dosage before asphyxia/reventilation decreased superoxide anion production to 3 +/- 1 pmol NBT/mm2.

ExcerptReference
" The difference in dosage form may partly account for this difference, but the benzbromarone also seems to be involved."( Kinetics of allopurinol and its metabolite oxypurinol after oral administration of allopurinol alone or associated with benzbromarone in man. Simultaneous assay of hypoxanthine and xanthine by gas chromatography-mass spectrometry.
Bargnoux, H; Berger, JA; Bussiere, JL; Chabard, JL; Lartigue-Mattei, C; Petit, J; Ristori, JM, 1991
)
" The extent of dosage was increased during the reperfusion without qualitative changes of the pattern of structural dosage."( Discrepancy between biochemical normalization and morphological recovery of jejunal mucosa during postischemic reperfusion in presence of the xanthine oxidase inhibitor oxypurinol.
Bimmler, M; David, H; Grune, T; Kowalewski, J; Siems, W, 1991
)
" Dosing with theophylline was used to produce 1MX as an intermediate metabolite in six healthy volunteers."( 1-Methylxanthine derived from theophylline as an in vivo biochemical probe of allopurinol effect.
Birkett, DJ; Day, RO; Miners, JO, 1991
)
"This study examined dosage prescribing patterns and steady-state oxipurinol plasma concentrations in 66 patients receiving chronic allopurinol therapy."( Dosage prescribing and plasma oxipurinol levels in patients receiving allopurinol therapy.
Boyle, RR; Francis, HW; Oliver, NW; Paterson, J; Peterson, GM; Taylor, GR; von Witt, RJ, 1990
)
" Increased OXY dosage (15 mg/kg) or allopurinol (40 mg/kg) had no greater effects."( Effects of xanthine oxidase inhibition on ischemic acute renal failure in the rat.
Gmur, DJ; Zager, RA, 1989
)
" The neutrophil dose-response curve for increase in XO paralleled closely the curve for neutrophil-mediated RPAEC cytotoxicity."( Xanthine oxidase activity in rat pulmonary artery endothelial cells and its alteration by activated neutrophils.
Gannon, DE; Phan, SH; Ryan, US; Varani, J; Ward, PA, 1989
)
" It was apparent that many patients were taking unnecessarily high daily doses of allopurinol and that renal status was not always considered when deciding dosage regimens of allopurinol."( Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion.
Birkett, DJ; Day, RO; Hayes, J; Miners, JO; Naidoo, D; Savdie, E; Whitehead, A, 1988
)
" Plasma oxipurinol concentrations correlated directly with both allopurinol dosage and with renal glomerular function as reflected by the plasma creatinine concentration."( Plasma oxipurinol concentrations during allopurinol therapy.
Cross, M; Emmerson, BT; Gordon, RB; Thomson, DB, 1987
)
" Monitoring of plasma oxipurinol levels (ideally less than 100 mumol/l) by high-pressure liquid chromatography is helpful for adjusting dosage in renal failure."( Allopurinol in renal failure and the tumour lysis syndrome.
Cameron, JS; Davies, PM; Morris, GS; Simmonds, HA, 1986
)
" Current use of rectal dosage forms as an adjunct in cancer chemotherapy should therefore be re-examined."( Allopurinol kinetics and bioavailability. Intravenous, oral and rectal administration.
Appelbaum, SJ; Dorr, RT; Mayersohn, M; Perrier, D, 1982
)
"The relative bioavailability of two commercial preparations of 100 mg and 300 mg allopurinol tablets was examined in two groups of 16 healthy human subjects, one for each dosage level."( The bioavailability of two commercial preparations of allopurinol tablets.
Kleinberg, SI; Marcus, M; Tse, FL, 1982
)
" In the group composed of patients with normal kidney function (CCr > or = 80 ml/min), increase in the dosage of allopurinol was associated with a linear increase in the serum concentration of oxipurinol."( [A study of serum oxipurinol concentration and renal function in patients administered allopurinol].
Saji, M, 1996
)
"The relationship between the plasma oxypurinol (the active metabolite of allopurinol) concentration at the midpoint of each caffeine dosage interval and the decrement in the urinary 1MX to 1MU ratio fitted well by a sigmoid Emax model."( 1-Methylxanthine derived from caffeine as a pharmacodynamic probe of oxypurinol effect.
Birkett, DJ; Day, RO; Lillywhite, KJ; Miners, JO; Valente, L, 1997
)
"In the first part of the study, allopurinol was administered IV at a dosage of 10 mg/kg of body weight to 3 dogs and 5 mg/kg to 3 dogs; the sequence was then reversed."( Bioavailability and pharmacokinetics of intravenously and orally administered allopurinol in healthy beagles.
Bartges, JW; Bird, KA; Chen, M; Felice, LJ; Koehler, LA; Osborne, CA; Sawchuk, RJ; Ulrich, LK, 1997
)
"To study the effect of a safe dosage of allopurinol on ischemia-reperfusion damage following aortic surgery, 24 patients undergoing either elective or acute aortic reconstruction, were randomized to receive allopurinol or placebo, yielding four groups: elective/placebo (EP), elective/allopurinol (EA), acute/placebo (AP) and acute/allopurinol (AA)."( Allopurinol dosage and effect on ischemia-reperfusion damage in elective and acute aortic surgery.
Berger, HM; Camps, J; Dulfer, FT; Hermans, J; Kievit, J; Smeets, HJ; Van Bockel, JH; van Milligen de Wit, AW,
)
" The rings were suspended for isometric tension recording and contracted with phenylephrine, and cumulative dose-response curves for ACh or calcium ionophore (A-23187) were generated."( Superoxide anion scavengers restore NO-mediated pulmonary vasodilation after lung transplantation.
Flavahan, NA; Murray, PA; Seki, S; Smedira, NG, 1999
)
" Four of these individuals were additionally dosed with 200 mg allopurinol intravenously."( Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects.
Krivanek, P; Oberbauer, R; Turnheim, K, 1999
)
" Allopurinol dosing guidelines and a therapeutic range for plasma oxypurinol levels have been published."( The optimal use of allopurinol: an audit of allopurinol use in South Auckland.
Gow, P; Raill, B; Sharples, K; Stamp, L, 2000
)
"We aimed to determine the appropriateness of allopurinol dosing according to current guidelines and to assess the relationship between plasma creatinine, oxypurinol and urate."( The optimal use of allopurinol: an audit of allopurinol use in South Auckland.
Gow, P; Raill, B; Sharples, K; Stamp, L, 2000
)
"There is poor adherence to the current recommended dosing guidelines for allopurinol."( The optimal use of allopurinol: an audit of allopurinol use in South Auckland.
Gow, P; Raill, B; Sharples, K; Stamp, L, 2000
)
" Venous blood samples were collected predose (at 0 hours) and 1, 2, 3, 4, 6, 8, 10 and 12 hours after dosage for determination of oxypurinol and/or probenecid concentrations."( Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects.
Day, RO; Graham, GG; McLachlan, AJ; Stocker, SL; Williams, KM, 2008
)
" The dosage of allopurinol in the D group was significantly lower than in the A and B groups."( [Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol].
Gomi, H; Hikita, M; Hosoya, T; Ichida, K; Ohno, I; Okabe, H; Saikawa, H; Uetake, D; Yamaguchi, Y, 2008
)
" Limiting allopurinol dosing to < or = 300 mg/d suboptimally controls hyperuricemia and fails to adequately prevent hypersensitivity reactions."( A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout.
Chao, J; Terkeltaub, R, 2009
)
" The effect of chronic aspirin and HCTZ dosing taken together upon the efficacy of chronic allopurinol therapy in patients with hyperuricaemia needs to be investigated."( Lack of effect of hydrochlorothiazide and low-dose aspirin on the renal clearance of urate and oxypurinol after a single dose of allopurinol in normal volunteers.
Day, RO; Graham, GG; Ng, DY; Stocker, SL; Williams, KM, 2011
)
" All doses except the 250 mg daily dose were divided and dosing was twice daily."( Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout.
Day, RO; Graham, GG; McLachlan, AJ; Stocker, SL; Williams, KM, 2011
)
" Model predictions showed a relationship between plasma oxypurinol and urate concentrations and failure to reach target oxypurinol concentrations using suggested allopurinol dosing guidelines."( The pharmacokinetics of oxypurinol in people with gout.
Day, RO; Graham, GG; Kirkpatrick, CM; McLachlan, AJ; Savic, RM; Stocker, SL; Williams, KM, 2012
)
" Exposure of BAECs (bovine aortic endothelial cells) to pharmacologically relevant dosage (12."( Inhibition of XO or NOX attenuates diethylstilbestrol-induced endothelial nitric oxide deficiency without affecting its effects on LNCaP cell invasion and apoptosis.
Cai, H; Nguyen, A; Youn, JY, 2012
)
" The model provides a basis for the rational dosing of allopurinol in clinical practice."( The population pharmacokinetics of allopurinol and oxypurinol in patients with gout.
Barclay, ML; Duffull, SB; Holford, NH; Merriman, TR; Stamp, LK; Wright, DF, 2013
)
" On 48% of occasions, the time of allopurinol dosing was recorded, while just 79 (19%) blood samples were collected 6-9 hours postdosing, the time window used to establish the therapeutic range for oxypurinol."( An audit of a therapeutic drug monitoring service for allopurinol therapy.
Day, RO; Graham, GG; Jones, G; Kannangara, DR; Ramasamy, SN; Ray, JE; Williams, KM, 2013
)
" The dosage used and the effect of allopurinol in this population, either or not undergoing therapeutic hypothermia (TH), were evaluated."( Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates.
Allegaert, K; Annink, KV; Bakkali, LE; Benders, MJNL; Chu, WY; Dorlo, TPC; Franz, AR; Hagen, A; Huitema, ADR; Maiwald, CA; Nijstad, AL; Schroth, M; van Bel, F; van Weissenbruch, MM, 2022
)
" The dosing regimen applied in the ALBINO trial leads to the targeted XO inhibition in neonates treated with or without TH."( Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates.
Allegaert, K; Annink, KV; Bakkali, LE; Benders, MJNL; Chu, WY; Dorlo, TPC; Franz, AR; Hagen, A; Huitema, ADR; Maiwald, CA; Nijstad, AL; Schroth, M; van Bel, F; van Weissenbruch, MM, 2022
)
" The aim of this study was to investigate whether anthropometric and socioeconomic factors and comorbidities could explain sex-related differences in concentrations and dosing for metoprolol and oxypurinol, the active metabolite of allopurinol."( Females present higher dose-adjusted drug concentrations of metoprolol and allopurinol/oxypurinol than males.
Busseuil, D; de Denus, S; Dubé, MP; Gaulin, MJ; Hindi, J; Jutras, M; Leclair, G; Meloche, M; Mongrain, I; Oussaïd, E; Pilon, MO; Rouleau, JL; St-Jean, I; Tardif, JC, 2023
)
"The proposed allopurinol dosing guide uses individuals' fat-free mass, renal function and SLC22A12 rs505802 and PDZK1 rs12129861 genotypes to achieve target SU."( Population pharmacokinetics, pharmacodynamics and pharmacogenetics modelling of oxypurinol in Hmong adults with gout and/or hyperuricemia.
Brundage, RC; Culhane-Pera, KA; Roman, YM; Straka, RJ; Wen, YF, 2023
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
EC 1.17.3.2 (xanthine oxidase) inhibitorAn EC 1.17.3.* (oxidoreductase acting on CH or CH2 with oxygen as acceptor) inhibitor that interferes with the action of xanthine oxidase (EC 1.17.3.2).
drug metabolitenull
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
pyrazolopyrimidine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency5.01190.044717.8581100.0000AID485294
thioredoxin reductaseRattus norvegicus (Norway rat)Potency0.10000.100020.879379.4328AID588453
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency0.48970.000214.376460.0339AID720691
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency74.86650.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency68.58960.005428.02631,258.9301AID1346982
gemininHomo sapiens (human)Potency1.58490.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Xanthine dehydrogenase/oxidaseHomo sapiens (human)Ki0.51750.00011.38097.3000AID1185461; AID1185462
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (27)

Processvia Protein(s)Taxonomy
allantoin metabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of protein phosphorylationXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of endothelial cell proliferationXanthine dehydrogenase/oxidaseHomo sapiens (human)
guanine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
inosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
deoxyinosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
adenosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
deoxyadenosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
deoxyguanosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
AMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
IMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
lactationXanthine dehydrogenase/oxidaseHomo sapiens (human)
hypoxanthine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
xanthine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of gene expressionXanthine dehydrogenase/oxidaseHomo sapiens (human)
iron-sulfur cluster assemblyXanthine dehydrogenase/oxidaseHomo sapiens (human)
amide catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of endothelial cell differentiationXanthine dehydrogenase/oxidaseHomo sapiens (human)
GMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
dGMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
dAMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionXanthine dehydrogenase/oxidaseHomo sapiens (human)
positive regulation of p38MAPK cascadeXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of vascular endothelial growth factor signaling pathwayXanthine dehydrogenase/oxidaseHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of vasculogenesisXanthine dehydrogenase/oxidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (11)

Processvia Protein(s)Taxonomy
xanthine dehydrogenase activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
xanthine oxidase activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
iron ion bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
protein bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
protein homodimerization activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
molybdopterin cofactor bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
flavin adenine dinucleotide bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
2 iron, 2 sulfur cluster bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
hypoxanthine dehydrogenase activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
hypoxanthine oxidase activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
FAD bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
cytosolXanthine dehydrogenase/oxidaseHomo sapiens (human)
extracellular spaceXanthine dehydrogenase/oxidaseHomo sapiens (human)
peroxisomeXanthine dehydrogenase/oxidaseHomo sapiens (human)
cytosolXanthine dehydrogenase/oxidaseHomo sapiens (human)
sarcoplasmic reticulumXanthine dehydrogenase/oxidaseHomo sapiens (human)
extracellular spaceXanthine dehydrogenase/oxidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (20)

Assay IDTitleYearJournalArticle
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID491531Binding affinity to Mycobacterium tuberculosis purine nucleoside phosphorylase by spectrophotometric analysis2010Bioorganic & medicinal chemistry, Jul-01, Volume: 18, Issue:13
Crystallographic and docking studies of purine nucleoside phosphorylase from Mycobacterium tuberculosis.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1185461Inhibition of human xanthine oxidase2014Journal of natural products, Jul-25, Volume: 77, Issue:7
X-ray crystal structure of a xanthine oxidase complex with the flavonoid inhibitor quercetin.
AID227718Binding energy by using the equation deltaG obsd = -RT ln KD1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Functional group contributions to drug-receptor interactions.
AID1185462Inhibition of oxidized form of human xanthine oxidase2014Journal of natural products, Jul-25, Volume: 77, Issue:7
X-ray crystal structure of a xanthine oxidase complex with the flavonoid inhibitor quercetin.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (451)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990131 (29.05)18.7374
1990's135 (29.93)18.2507
2000's91 (20.18)29.6817
2010's73 (16.19)24.3611
2020's21 (4.66)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials45 (9.85%)5.53%
Reviews12 (2.63%)6.00%
Case Studies24 (5.25%)4.05%
Observational0 (0.00%)0.25%
Other376 (82.28%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Evaluation of the Mechanism of NO Formation and Pharmacokinetics of Systemic Nitrite Infusion[NCT00102271]Phase 136 participants (Actual)Interventional2005-01-19Completed
Atorvastatin Therapy To Improve Endothelial Function in Sickle Cell Disease[NCT00072826]Phase 144 participants (Actual)Interventional2003-11-04Completed
A Phase II-III Prospective, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oxypurinol Added to Standard Therapy in Patients With NYHA Class III-IV Congestive Heart Failure[NCT00063687]Phase 2/Phase 3400 participants Interventional2003-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]